{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:21:03Z","timestamp":1776370863378,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,2,7]],"date-time":"2010-02-07T00:00:00Z","timestamp":1265500800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00345-010-0513-y","type":"journal-article","created":{"date-parts":[[2010,2,6]],"date-time":"2010-02-06T02:28:18Z","timestamp":1265423298000},"page":"651-656","source":"Crossref","is-referenced-by-count":23,"title":["The effect of tolterodine 4 and 8\u00a0mg on the heart rate variability in healthy subjects"],"prefix":"10.1007","volume":"28","author":[{"given":"Maya","family":"Schiffers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sauermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Schurch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Mehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,7]]},"reference":[{"key":"513_CR1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","volume":"87","author":"I Milsom","year":"2001","unstructured":"Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760\u2013766","journal-title":"BJU Int"},{"key":"513_CR2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327\u2013336","journal-title":"World J Urol"},{"key":"513_CR3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.eururo.2005.04.026","volume":"48","author":"C Temml","year":"2005","unstructured":"Temml C, Heidler S, Ponholzer A et al (2005) Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 48:622\u2013627","journal-title":"Eur Urol"},{"key":"513_CR4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306\u20131314 (discussion 1314\u20131315)","journal-title":"Eur Urol"},{"key":"513_CR5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2009.01.007","volume":"55","author":"AL Wennberg","year":"2009","unstructured":"Wennberg AL, Molander U, Fall M et al (2009) A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol 55:783\u2013791","journal-title":"Eur Urol"},{"key":"513_CR6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","volume":"54","author":"G Novara","year":"2008","unstructured":"Novara G, Galfano A, Secco S et al (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740\u2013763","journal-title":"Eur Urol"},{"key":"513_CR7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1074248408325404","volume":"13","author":"B Olshansky","year":"2008","unstructured":"Olshansky B, Ebinger U, Brum J et al (2008) Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants \u226550\u00a0years. J Cardiovasc Pharmacol Ther 13:241\u2013251","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"513_CR8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1464-410X.2007.07100.x","volume":"100","author":"KE Andersson","year":"2007","unstructured":"Andersson KE, Olshansky B (2007) Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 100:1007\u20131014","journal-title":"BJU Int"},{"key":"513_CR9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00002018-200831060-00005","volume":"31","author":"MC Michel","year":"2008","unstructured":"Michel MC, Wetterauer U, Vogel M et al (2008) Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf 31:505\u2013514","journal-title":"Drug Saf"},{"key":"513_CR10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743\u2013753","journal-title":"Circulation"},{"key":"513_CR11","doi-asserted-by":"crossref","unstructured":"Andersson KE, Sarawate C, Kahler KH et al (2009) Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int [Epub ahead of print]","DOI":"10.1111\/j.1464-410X.2009.09073.x"},{"key":"513_CR12","doi-asserted-by":"crossref","first-page":"b219","DOI":"10.1136\/bmj.b219","volume":"338","author":"J Hsia","year":"2009","unstructured":"Hsia J, Larson JC, Ockene JK et al (2009) Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 338:b219","journal-title":"BMJ"},{"key":"513_CR13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/oxfordjournals.aje.a009049","volume":"145","author":"JM Dekker","year":"1997","unstructured":"Dekker JM, Schouten EG, Klootwijk P et al (1997) Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study. Am J Epidemiol 145:899\u2013908","journal-title":"Am J Epidemiol"},{"key":"513_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10654-009-9317-z","volume":"24","author":"KH Greiser","year":"2009","unstructured":"Greiser KH, Kluttig A, Schumann B et al (2009) Cardiovascular diseases, risk factors and short-term heart rate variability in an elderly general population: the CARLA study 2002\u20132006. Eur J Epidemiol 24:123\u2013142","journal-title":"Eur J Epidemiol"},{"key":"513_CR15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/01.CIR.93.5.1043","volume":"93","author":"Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","year":"1996","unstructured":"Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93:1043\u20131065","journal-title":"Circulation"},{"key":"513_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF02322053","volume":"11","author":"MW Agelink","year":"2001","unstructured":"Agelink MW, Malessa R, Baumann B et al (2001) Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate. Clin Auton Res 11:99\u2013108","journal-title":"Clin Auton Res"},{"key":"513_CR17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","volume":"327","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Andersson KE, Gillberg PG et al (1997) Tolterodine\u2014a new bladder-selective antimuscarinic agent. Eur J Pharmacol 327:195\u2013207","journal-title":"Eur J Pharmacol"},{"key":"513_CR18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","volume":"3","author":"KE Andersson","year":"2004","unstructured":"Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3:46\u201353","journal-title":"Lancet Neurol"},{"key":"513_CR19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1172\/JCI1113","volume":"101","author":"OE Brodde","year":"1998","unstructured":"Brodde OE, Konschak U, Becker K et al (1998) Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies. J Clin Invest 101:471\u2013478","journal-title":"J Clin Invest"},{"key":"513_CR20","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00228-005-0953-2","volume":"61","author":"J Penttila","year":"2005","unstructured":"Penttila J, Kuusela T, Scheinin H (2005) Analysis of rapid heart rate variability in the assessment of anticholinergic drug effects in humans. Eur J Clin Pharmacol 61:559\u2013565","journal-title":"Eur J Clin Pharmacol"},{"key":"513_CR21","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1540-8167.2006.00501.x","volume":"17","author":"KC Bilchick","year":"2006","unstructured":"Bilchick KC, Berger RD (2006) Heart rate variability. J Cardiovasc Electrophysiol 17:691\u2013694","journal-title":"J Cardiovasc Electrophysiol"},{"key":"513_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-5273(02)00057-8","volume":"84","author":"J Pumprla","year":"2002","unstructured":"Pumprla J, Howorka K, Groves D et al (2002) Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol 84:1\u201314","journal-title":"Int J Cardiol"},{"key":"513_CR23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/01.CIR.85.1.164","volume":"85","author":"JT Bigger Jr","year":"1992","unstructured":"Bigger JT Jr, Fleiss JL, Steinman RC et al (1992) Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 85:164\u2013171","journal-title":"Circulation"},{"key":"513_CR24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","volume":"85","author":"MB Chancellor","year":"2006","unstructured":"Chancellor MB, Anderson RU, Boone TB (2006) Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 85:536\u2013545","journal-title":"Am J Phys Med Rehabil"},{"key":"513_CR25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/nau.20289","volume":"25","author":"M Horstmann","year":"2006","unstructured":"Horstmann M, Schaefer T, Aguilar Y et al (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25:441\u2013445","journal-title":"Neurourol Urodyn"},{"key":"513_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1034\/j.1600-0404.2000.101002085.x","volume":"101","author":"AR Acevedo","year":"2000","unstructured":"Acevedo AR, Nava C, Arriada N et al (2000) Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand 101:85\u201388","journal-title":"Acta Neurol Scand"},{"key":"513_CR27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pmr.2007.02.003","volume":"18","author":"SV Garstang","year":"2007","unstructured":"Garstang SV, Miller-Smith SA (2007) Autonomic nervous system dysfunction after spinal cord injury. Phys Med Rehabil Clin N Am 18:275\u2013296 vi\u2013vii","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"513_CR28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","volume":"40","author":"B Olsson","year":"2001","unstructured":"Olsson B, Szamosi J (2001) Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 40:227\u2013235","journal-title":"Clin Pharmacokinet"},{"key":"513_CR29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.ede.0000158743.90664.a7","volume":"16","author":"C Huerta","year":"2005","unstructured":"Huerta C, Lanes SF, Garcia Rodriguez LA (2005) Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 16:360\u2013366","journal-title":"Epidemiology"},{"key":"513_CR30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0031-6997(24)01425-X","volume":"51","author":"OE Brodde","year":"1999","unstructured":"Brodde OE, Michel MC (1999) Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51:651\u2013690","journal-title":"Pharmacol Rev"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0513-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-010-0513-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-010-0513-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:48:00Z","timestamp":1739839680000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-010-0513-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,7]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s00345-010-0513-y","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,7]]}}}